GLP-1 Drug Examples & Comparison
From Byetta to Wegovy: a complete guide to GLP-1 medications approved for weight loss and diabetes management.
What Are GLP-1 Drugs?
GLP-1 (glucagon-like peptide-1) medications mimic a natural hormone that regulates blood sugar and appetite. Originally developed for type 2 diabetes, newer formulations are approved specifically for weight loss. The drug family spans nearly 20 years of innovation—from daily injections to once-weekly shots to once-daily oral tablets.
Complete GLP-1 Drug Comparison
This table covers all major GLP-1 medications in the U.S. market, organized by generation and approval status.
| Brand Name | Active Ingredient | Approved For | How Taken | Typical Weight Loss |
|---|---|---|---|---|
| Wegovy | semaglutide | Weight loss (BMI ≥27) | Weekly injection | 15–22% of body weight |
| Zepbound | tirzepatide | Weight loss (BMI ≥27) | Weekly injection | 17–22% of body weight |
| Ozempic | semaglutide | Type 2 diabetes | Weekly injection | 3–5% (off-label for weight loss) |
| Mounjaro | tirzepatide | Type 2 diabetes | Weekly injection | 4–6% (off-label for weight loss) |
| Rybelsus | semaglutide | Type 2 diabetes | Daily oral tablet | 2–4% |
| Saxenda | liraglutide | Weight loss (BMI ≥30) | Daily injection | 5–8% of body weight |
| Victoza | liraglutide | Type 2 diabetes | Daily injection | 2–4% |
| Trulicity | dulaglutide | Type 2 diabetes | Weekly injection | 1–3% |
| Byetta | exenatide | Type 2 diabetes | Twice-daily injection | 2–4% |
Second-Generation Drugs (2021–Present)
The newest GLP-1 medications deliver the strongest weight loss results and are driving the current surge in popularity.
Wegovy (semaglutide) — FDA-approved for weight loss in 2021. Weekly injection. Strongest clinical data shows 15–22% weight loss over 68 weeks. Most commonly prescribed weight-loss drug in the U.S. Long waitlists due to demand.
Zepbound (tirzepatide) — FDA-approved for weight loss in late 2023. Dual-action mechanism (GLP-1 + GIP). Slightly higher weight loss than Wegovy (17–22% in trials). Weekly injection. Newer drug with growing availability.
Ozempic & Mounjaro — Originally approved for type 2 diabetes, these are prescribed off-label for weight loss due to strong efficacy and lower cost than Wegovy/Zepbound. Both weekly injections. Off-label prescribing is legal but requires a doctor's judgment.
The Oral Option: Rybelsus
Rybelsus is the only GLP-1 medication taken by mouth (daily tablet) rather than injection. It's approved for type 2 diabetes only, not weight loss. Weight loss is modest (2–4%), and absorption is finicky—must be taken on an empty stomach 30 minutes before food or drink. Most people prefer injections for better results.
First-Generation Drugs (2005–2020)
These older medications are less potent than newer options but remain available, cheaper, and easier to access. Most are approved for diabetes; weight loss is a secondary benefit.
Saxenda (liraglutide) — FDA-approved for weight loss in 2014. Daily injection. Delivers 5–8% weight loss. Widely available and covered by insurance. Fewer side effects than newer drugs but requires daily dosing instead of weekly.
Victoza & Trulicity — Both approved for diabetes. Liraglutide (Victoza) requires daily injections with modest weight loss (2–4%). Dulaglutide (Trulicity) is weekly with minimal weight loss benefit (1–3%). Rarely prescribed for weight loss specifically.
Byetta (exenatide) — The original GLP-1 drug (2005). Requires twice-daily injections. Minimal weight loss (2–4%). Rarely used today except in cases where newer drugs are contraindicated.
Why the Differences?
Newer drugs are stronger because they:
- Last longer in your system — Weekly injections instead of daily, which improves adherence
- Act on more pathways — Tirzepatide (Zepbound, Mounjaro) targets both GLP-1 and GIP receptors, producing stronger appetite suppression
- Reach higher doses safely — Better tolerability at higher concentrations means more weight loss before side effects become limiting
How to Choose
Your doctor will consider:
- Budget — Ozempic/Mounjaro (diabetes) cost $200–400/month; Wegovy/Zepbound $1,500–1,800 without insurance
- Goal — Diabetes management vs. weight loss only
- Medical history — Some drugs are contraindicated in thyroid cancer, pancreatitis, or certain kidney conditions
- Availability — Waitlists are shortest for first-gen and off-label diabetes options
Bottom Line
GLP-1 drugs work. The question is which one fits your timeline, budget, and goals. Newest ≠ always best—Saxenda is proven, available, and affordable; Wegovy and Zepbound are stronger but harder to access. Talk with your doctor about what's realistic for your situation.
References
Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.